Johnson & Johnson Posts Positive Phase 1b/2 Data Of Amivantamab Combo In Head And Neck Cancer

Johnson & Johnson reported new Cohort 5 results from the Phase 1b/2 OrigAMI-4 study: 65% of responses remained ongoing at the clinical cut-off with first-line subcutaneous amivantamab and hyaluronidase-lpuj plus a PD-1 inhibitor. The provided article text ends before naming the inhibitor or giving further efficacy and safety data.